Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

76.000
+2.2503.05%
Volume:2.57M
Turnover:192.12M
Market Cap:42.83B
PE:50.38
High:76.200
Open:73.800
Low:72.600
Close:73.750
52wk High:126.600
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:1.30
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.508
ROE:109.10%
ROA:39.01%
PB:4.41
PE(LYR):50.38
PS:4.58

Loading ...

Movement Alert|RemeGen Rises 5.31% in Regular Trading, HK Biotech Sector Extends Rebound as Lock-Up Share Selling Restrictions Ease Overhang Concerns

Market Focus
·
Jun 24

Movement Alert|RemeGen Rises 5.02% in Regular Trading, Sector Rebounds as Lock-up Expiry Selling Pressure Eased by Regulatory Restriction

Market Focus
·
Jun 23

Hong Kong Stocks Flat In Morning Trading

Dow Jones
·
Jun 23

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

Remegen to Release 193 Million Locked Shares on July 1

Stock News
·
Jun 22

Movement Alert|RemeGen Falls 5.33% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure

Market Focus
·
Jun 22

RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative

Simply Wall St.
·
Jun 21

RemeGen (SEHK:9995) Stock Could Be 39% Below Fair Value After Telitacicept Approvals

Simply Wall St.
·
Jun 19

REMEGEN Announces Board Re-Elections, Including Chairman and CEO

Stock News
·
Jun 16

Movement Alert|RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure

Market Focus
·
Jun 16

Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress

Stock News
·
Jun 12

Movement Alert|RemeGen Rises 5.38% in Regular Trading, Dual Indication Approval for Core Drug Telitacicept Continues to Boost Sentiment

Market Focus
·
Jun 12

RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains

Simply Wall St.
·
Jun 10

BUZZ-RemeGen Shanghai shares jump most in 10 weeks on China nod for new drug marketing

Reuters
·
Jun 09

New Drug from REMEGEN Gains Approval, Boosting A and H Share Prices; Pharmaceutical ETF Rebounds, Hong Kong Stock Connect Innovative Drug ETF Maintains Premium

Deep News
·
Jun 09

REMEGEN Shares Surge on Dual Indication Approvals for Telitacicept

Stock News
·
Jun 09

Movement Alert|RemeGen Rises 5.68% in Regular Trading, Core Product Telitacicept Receives Approval for Two New Indications

Market Focus
·
Jun 09

Key Corporate Developments and Share Repurchases Highlight Hong Kong Market Activity

Stock News
·
Jun 09

RemeGen Gets Marketing Nod for Sjögren's Syndrome Drug in China

MT Newswires Live
·
Jun 08

RemeGen Secures NMPA Approval for Telitacicept’s New Indication Targeting Sjögren’s Disease

Bulletin Express
·
Jun 08